Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VaxInfectio), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Division of Neurology, Antwerp University Hospital, Edegem, Belgium.
Front Immunol. 2021 Feb 19;12:624685. doi: 10.3389/fimmu.2021.624685. eCollection 2021.
Antigen-specific therapy for multiple sclerosis may lead to a more effective therapy by induction of tolerance to a wide range of myelin-derived antigens without hampering the normal surveillance and effector function of the immune system. Numerous attempts to restore tolerance toward myelin-derived antigens have been made over the past decades, both in animal models of multiple sclerosis and in clinical trials for multiple sclerosis patients. In this review, we will give an overview of the current approaches for antigen-specific therapy that are in clinical development for multiple sclerosis as well provide an insight into the challenges for future antigen-specific treatment strategies for multiple sclerosis.
多发性硬化症的抗原特异性治疗可能通过诱导对广泛的髓鞘衍生抗原的耐受性而导致更有效的治疗，而不会损害免疫系统的正常监测和效应功能。在过去的几十年中，无论是在多发性硬化症的动物模型中还是在多发性硬化症患者的临床试验中，人们都尝试了无数次来恢复对髓鞘衍生抗原的耐受性。在这篇综述中，我们将概述目前正在临床开发用于多发性硬化症的抗原特异性治疗方法，并深入了解多发性硬化症的未来抗原特异性治疗策略所面临的挑战。
